A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.

Vanderbilt researchers have developed a risk stratification tool to predict outcomes and avoid unnecessary hospital admissions after emergency department visits for acute heart failure.

Vanderbilt researchers developed new prognostic models for breast cancer outcomes and found that adding postdiagnostic weight change as a factor improves the prediction.

Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.

New investments in clinical programs at Vanderbilt University Medical Center are increasingly contingent upon studies to validate claims of benefit and the potential for scalability and spread.

Geographically targeted efforts to prevent children being placed in out-of-home care might be possible, Vanderbilt researchers report.